01415: Development of Anti-IgE Peptide for Treatment of Canine Allergy

Grant Status: Closed

Grant Amount: $84,861
Bruce Hammerberg, DVM, PhD; North Carolina State University
January 1, 2011 - December 31, 2012

Sponsor(s): Berner Lovers, Flat-Coated Retriever Foundation, Golden Retriever Foundation

Breed(s): -All Dogs
Research Program Area: Dermatology and Allergic Disease
Donate to Support this Research Program Area

Project Summary

1) To create a recombinant, non-anaphylactic, single-chain antibody fragment (scFv) with high affinity for canine IgE from the variable region gene sequences of mAb 5.91. The sequence for the light chain variable region of mAb 5.91 was completed in April, 2011. The sequence for the heavy chain variable region was completed in October, 2011. Linkage of the two sequences and expression of a recombinant scFv of mAb 5.91 with confirmation of high affinity binding to canine IgE was completed in November, 2011. A Fab fragment was produced from the whole molecule mAb 5.91 and used in flow cytometry assays as a model for the recombinant scFv version of the antibody by May, 2011. Whole blood from allergic dogs was processed and assayed. Results showed that the whole mAb 5.91 molecule reduced the amount of binding of canine IgE to the monocyte cell population from 15% to 7.7%. Moreover, the intact mAb 5.91 was able to bind the free IgE to prevent it from binding cell surface receptors. However, whole molecule mAb 5.91 complexed with canine IgE bound to 13.7% of the lymphocyte cell population possibly reacting with IgG Fc receptors. The Fab fragment of mAb 5.91, pre-incubated with canine IgE, reduced the binding of canine IgE to the monocyte cell population from 15% to 5.6%. This demonstrated that the Fab fragment of mAb 5.91 was even more effective in reducing the binding of IgE to the monocyte cell population than the intact mAb 5.91. There was no evidence of Fab fragment complexed with canine IgE binding to lymphocytes as previously seen with intact mAb 5.91. These preliminary results indicate that the recombinant scFv form of the mAb 5.91 will be more effective at blocking IgE binding to cell surface receptors as well as decreasing the potential of cross reactivity of the lymphocyte cell population with the IgG Fc receptors than the original mAb 5.91. 2) To generate a plant-derived recombinant, nonanaphylactic, scFv with high affinity for IgE that can be scaled up for production at kilogram amounts. To be completed in the second year. Gene constructs of the newly made 5.91-scFv were designed to target the chloroplast and ER regions of the tobacco leaf cells. Both gene constructs were inserted into a PVX pGR106 amplicon vector and amplified in E.coli. The purified 5.91scFv-pGR106 constructs are being used to transform Agrobacterium tumefaciens strain GV3101. However, problems have been encountered during transformation attempts of Agrobacterium tumefaciens with the purified 5.91scFv-pGR106 constructs. A second round of transformation is being performed at this time. TEV-B is a transgenic tobacco plant that expresses a mutated P1/HC-Pro suppressor of Post Transcriptional Gene Silencing. It has been shown that this line of tobacco plants produces higher protein yields than wild type varieties of tobacco including Nicotiana benthamiana. TEV-B seeds were planted on May 23rd and TEV-B plants should be ready for infection in July. TEV-B plants were Agroinfected with Agrobacterium tumefaciens GV3101 containing the gene 5.91scFv::chloro gene construct. Total protein was extracted from 2kg of transgenic leaf tissue. Crude extract was clarified from photosynthetic proteins and polyphenols that may interact with downstream applications. Binding activity of the 5.91scFv in the extract was confirmed on ELISA and was later compared to the activity of 5.91Fab and intact mAb 5.91 in whole blood and canine mast cells flow cytometry assays.


Hammerberg, B., Olivry, T., & Orton, S. M. (2001). Skin mast cell histamine release following stem cell factor and high-affinity immunoglobulin E receptor cross-linking in dogs with atopic dermatitis. Veterinary Dermatology, 12(6), 339–346. https://doi.org/10.1046/j.0959-4493.2001.00273.x

Help Future Generations of Dogs

Participate in canine health research by providing samples or by enrolling in a clinical trial. Samples are needed from healthy dogs and dogs affected by specific diseases.

Learn How to Help

Get Canine Health News:
Please leave this field empty
American Kennel Club Canine Health Foundation, Inc

8051 Arco Corporate Dr.
Suite 300
Raleigh, NC 27617

Tax ID# 13-3813813


© 2021 AKC Canine Health Foundation | Privacy Policy | Site Map

Site by Blackbaud, Inc.